# Perpetua Medical

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/perpetuamedical).

## Overview

Perpetua Medical is a Swedish acquisition company focused on buying and owning profitable, product-oriented businesses in the healthcare sector. It operates through a decentralized group structure, with independent subsidiaries responsible for day-to-day operations and commercial decisions. The company is headquartered in Uppsala and its shares trade on Nasdaq First North Stockholm under the ticker PERP B.

## Products & services

• Acquisition and ownership of healthcare businesses
• Decentralized subsidiary management model
• Product-oriented medical technology operations
• Portfolio development through add-on acquisitions
• Licensing and divestment of legacy healthcare assets

- **Healthcare acquisitions** (0%) — Buying and owning profitable healthcare companies as long-term holdings.
- **Medical technology operations** (100%) — Operating product-based healthcare businesses through subsidiaries.
- **Licensing and asset monetization** (0%) — Licensing and selling legacy products and related rights.

- Acquisition and ownership of healthcare businesses
- Decentralized subsidiary management model
- Product-oriented medical technology operations
- Portfolio development through add-on acquisitions
- Licensing and divestment of legacy healthcare assets

## Customers

Perpetua Medical sells through its operating subsidiaries to healthcare-related customers that need specialized medical technology products and related commercial support. The customer base is therefore defined by the portfolio companies it owns, rather than by a single unified end market. In practice, buyers include hospitals, healthcare providers, distributors, and other commercial partners depending on the subsidiary and product line.

- **Healthcare product customers** (primary) — Hospitals, clinics, and other healthcare users buying medical technology products from subsidiaries.
- **Distributors and channel partners** (secondary) — Partners that sell subsidiary products into local healthcare markets.
- **Licensing counterparties** (secondary) — Companies or partners that obtain rights to sell legacy products or assets.

- Hospitals and clinical users buying medical technology products
- Healthcare distributors reselling subsidiary products
- Commercial partners licensing or selling legacy products
- End customers of portfolio companies in the healthcare sector

## Geography

Perpetua Medical is headquartered in Uppsala, Sweden, and is listed in Stockholm. The reports also reference U.S. market activity through licensing and divestment arrangements, showing that the company’s portfolio can have cross-border commercial exposure even when the parent is Swedish. Geography matters because subsidiary operations, customer access, and partner relationships can differ materially by market.

- Headquartered in Uppsala, Sweden
- Listed on Nasdaq First North Stockholm
- U.S. market exposure through licensing and asset sales
- Subsidiary operations may span multiple healthcare markets

## Strategy

The company’s strategy is to acquire profitable, product-oriented healthcare businesses and hold them without a fixed exit horizon. It emphasizes a decentralized ownership model so each subsidiary can operate independently while the parent focuses on capital allocation and portfolio building. The reports also show a continued focus on building an acquisition pipeline and financing capacity to support future transactions.

- **Build and execute the acquisition pipeline** (short-term) — Growth depends on completing new healthcare acquisitions and expanding the portfolio.
- **Maintain decentralized subsidiary ownership** (medium-term) — Independent operating companies are intended to preserve entrepreneurial focus and value creation.
- **Strengthen financing capacity for acquisitions** (short-term) — Acquisition-led growth requires access to capital for transactions and working capital.

- Acquire profitable healthcare businesses with product exposure
- Use decentralized subsidiaries to preserve operating autonomy
- Build a pipeline of targets and pursue parallel deal processes
- Support acquisitions with equity financing and capital planning

## Risks

Perpetua Medical’s value depends heavily on the performance and valuation of its subsidiaries, which makes goodwill impairment and acquisition execution key risks. As an acquisition-led healthcare group, it is also exposed to deal timing, financing availability, and the commercial performance of the businesses it buys. Legacy asset disposals, partner dependence, and product-development uncertainty add further execution and valuation risk.

- **Goodwill impairment** [high] — Acquired businesses are tested at the subsidiary level and value depends on future cash flows.
- **Acquisition execution risk** [high] — The business model relies on finding, negotiating, and closing suitable healthcare targets.
- **Financing and dilution risk** [medium] — Acquisitions and portfolio expansion depend on access to equity capital.
- **Supplier and partner concentration** [medium] — Subsidiaries may rely on a limited number of distributors or suppliers.
- **Product development risk** [medium] — Portfolio companies may invest in products that do not meet technical or market expectations.

- Goodwill and acquisition values can be impaired if subsidiaries underperform
- Deal execution risk is high because growth depends on completing acquisitions
- Financing risk matters because acquisitions require external capital
- Dependence on a few suppliers or partners can disrupt subsidiary operations
- Product development in portfolio companies may fail or take longer than planned

## Accounting

The most important accounting judgments are tied to acquisitions, especially the allocation of purchase price to customer contracts and goodwill. Management also uses estimates for contingent consideration and impairment testing, both of which can materially change reported assets and earnings. The company’s legacy asset sale created deferred payment receivables, so collectability and fair value judgments also matter.

- **Purchase price allocation** — Affects intangible assets and future amortization
- **Goodwill impairment testing** — Can create large non-cash write-downs
- **Contingent consideration** — Affects liabilities and acquisition cost
- **Deferred purchase price receivables** — Creates credit and timing risk in reported assets

- Purchase price allocation affects goodwill and customer contract values
- Goodwill impairment testing depends on forecast cash flows and discount rates
- Contingent consideration is valued at zero when payment is not sufficiently certain
- Deferred sale proceeds create receivable and collectability judgments
- Foreign-currency transactions can affect results when assets are sold abroad

---

*Last updated: 2026-08-11T04:04:55.227588+00:00*